Bronchogen: lung-supporting peptide supplement from Russia
A short synthetic peptide that, in lab cell tests, switches on genes linked to a healthy lung airway lining; sold as a supplement in Russia, not approved as a drug anywhere.
- Class
- Khavinson-program bioregulator tetrapeptide
- Status
- Not approved by any major regulatory authority
- Best-supported effect
- Upregulation of bronchial epithelial genes (NKX2-1, MUC4, MUC5AC) in bronchial epithelial cell models (in vitro, Khavinson-group data only)
- Main caveat
- Entire positive evidence base from a single research group; human observational data involve only combined Bronchogen + Chonluten protocols with no individual attribution possible; no independent Western replication or controlled human trial present in source file
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Khavinson-program bioregulator tetrapeptide
Evidence tier: In vitro / assay evidence
Status: Not approved by any major regulatory authority; sold as an oral supplement / functional food in Russia; reaches Western users through research-chemical channels
Best-supported effect: Upregulation of bronchial epithelial genes (NKX2-1, MUC4, MUC5AC) in bronchial epithelial cell models (in vitro, Khavinson-group data)
Main caveat: The entire positive evidence base comes from a single research group; human observational data involve only combined Bronchogen + Chonluten protocols with no individual attribution possible; no independent Western replication or controlled human trial is present
What this is
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, AEDL) developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology as part of the short peptide bioregulator program. It is classified within that system as a lung/bronchial tissue-specific Cytogen — a chemically defined peptide designed to mirror the activity of a broader tissue-derived fraction. Within the Khavinson respiratory pair, Bronchogen is framed as targeting bronchial epithelial cell differentiation and mucin-producing machinery, while the companion peptide Chonluten (Glu-Asp-Gly) is positioned toward stress-protective and anti-inflammatory gene programs in the same tissue. Bronchogen reaches Western users primarily as an oral capsule or research-chemical preparation; neither represents a validated therapeutic pathway.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Anecdotal / combination-only | Observational reports from the Khavinson program describe use in chronic bronchitis with asthmatic component, always co-administered with Chonluten; individual attribution to Bronchogen is not possible; no randomized controlled trials are indexed in Western databases |
| Animal | None identified | No standalone in vivo animal experiment data are identified; studies labeled "animal" in available literature refer to bronchial epithelial cell models, which are in vitro |
| In vitro | Weak | Cell model studies from the Khavinson group report AEDL-mediated upregulation of NKX2-1, MUC4, and MUC5AC in bronchial epithelial cells; no independent laboratory has replicated these findings |
| Computational | Weak | Molecular modeling from the Khavinson program proposes LAT-family amino acid transporters as a cellular uptake route for AEDL; no independent docking or structure-prediction data are present |
| Mechanism | Plausible within framework | Proposed direct interaction of AEDL with CpG-rich DNA regulatory regions and histone remodeling to alter tissue-specific gene cluster accessibility; internally consistent with identifiable gene targets but the core "short peptide binds DNA directly" claim has not been independently validated |
The entirety of the published evidence base is concentrated within the Khavinson research orbit at a single institute. Independent Western replication of the AEDL-specific gene-regulation signal has not been published. This is a significant limitation of the current evidence base.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Upregulates bronchial epithelial genes (NKX2-1, MUC4, MUC5AC) in cell models | Supported (in vitro) | In vitro | Low — Khavinson-group cell models only; no independent replication |
| Improves outcomes in chronic bronchitis with asthmatic component | Not established | Human (combination-only observational) | Low — always co-administered with Chonluten; individual contribution of Bronchogen cannot be assessed from available data |
| Effective for COPD or age-related respiratory decline | Not established | None identified in source | Low — mentioned only as framing context; no dedicated study for this indication is present |
| Anti-aging of lung tissue via gene expression modulation | Weak (in vitro) | In vitro | Low — extrapolated from cell-model gene expression data in available literature; no in vivo or human confirmation |
| Short tetrapeptide directly binds DNA to alter chromatin accessibility | Weak / contested | In vitro / computational | Low — proposed by the Khavinson program; described in available literature as contested outside that research orbit; not independently validated |
Assay conditions
This section reports concentrations and conditions used in assays. It does not establish animal or human exposure.
| Context | System | Assay condition | Timepoint | Endpoint | Limitation |
|---|---|---|---|---|---|
| In vitro gene expression | Bronchial epithelial cell models | AEDL peptide; exact concentration not individually extracted's available literature | Not individually extracted | NKX2-1, MUC4, MUC5AC gene expression | Khavinson-group data only; no independent replication; in vitro finding does not establish in vivo or clinical effect |
Assay limitations
- All in vitro evidence originates from a single research group; no independent laboratory has replicated the AEDL-specific gene-regulation signal in bronchial epithelial cell models.
- Cell-model gene expression data does not establish that exogenous AEDL administration produces the same gene-regulation signal in intact respiratory epithelium in vivo.
- Exact peptide concentrations and assay protocols are not individually detailed, reproducibility and dose-relevance of reported effects cannot be assessed.
- No animal toxicology or human safety data meeting Western regulatory standards are described.
- The proposed mechanism of direct DNA interaction by a tetrapeptide is contested outside the Khavinson program and has not been independently validated; this affects interpretation of all assay-level findings.
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved | Not approved for any indication; not recognized as a dietary supplement ingredient; Per available sources, it is not on the FDA list of peptides eligible for 503A compounding |
| EU (EMA) | Not authorized | Per available sources, no EMA authorization |
| UK (MHRA) | Not authorized | Per available sources, no MHRA authorization |
| Canada (Health Canada) | Not authorized | Per available sources, no Health Canada authorization |
| Australia (TGA) | Not authorized | Per available sources, no TGA authorization |
| Russia | Sold as supplement / functional food | Marketed as oral capsule under Khavinson Peptides brand (Peptides.ru); not registered as a prescription medicine; source-bundle reported status |
| WADA | Unclear — per available sources caution for injectable form | Not specifically named on the WADA Prohibited List per the available literature; source notes that because no governmental regulatory authority approves Bronchogen for human therapeutic use, injectable use by athletes subject to the WADA code can reasonably be read as falling under the S0 catch-all; current WADA list status not independently refreshed in this card |
per available sources regulatory status; not independently verified against current official regulatory lists in this card.
Mechanism
Bronchogen (Ala-Glu-Asp-Leu) is proposed by the Khavinson group to penetrate cell membranes — facilitated by its small molecular size and, per molecular modeling from the same group, potentially by LAT-family amino acid transporters — and to interact with CpG-rich DNA regulatory regions in respiratory epithelial cells. In bronchial epithelial cell models, the group reports that AEDL upregulates the thyroid transcription factor NKX2-1 (TTF-1), a master regulator of lung and bronchial epithelial differentiation, and the mucin genes MUC4 and MUC5AC, which encode components of the airway mucus barrier. The broader Khavinson mechanistic model invokes direct sequence-specific binding of short peptides to chromatin-associated DNA sequences and associated histone interactions to alter tissue-specific gene cluster accessibility.
The AEDL mechanism is internally consistent with identifiable gene targets, but the "short peptide directly binds DNA" component of this framework has not been independently validated outside the Khavinson research program. No bronchoalveolar or pulmonary biomarker data in humans confirms that the in vitro gene-regulation signal translates to any clinical effect. The molecular modeling proposing LAT-family transporter-mediated uptake is from the same research group and has not been independently replicated.
Chemistry
| Field | Value |
|---|---|
| Sequence | Ala-Glu-Asp-Leu (AEDL) |
| Length | 4 amino acids |
| Topology | Linear |
| Modifications | None reported in source |
| Molecular weight | not individually extracted's available literature |
| Formula | not individually extracted's available literature |
| CAS | not individually extracted's available literature |
| Sequence confidence | Consistent across source descriptions |
Open questions
- Independent replication: No Western respiratory biology laboratory has independently replicated any AEDL-specific cell-model finding. Independent replication is the most critical missing piece for any confidence in the mechanistic claims.
- Mechanism validation: The proposed direct short-peptide DNA-binding mechanism remains unvalidated outside the Khavinson program. Whether this mechanism is operative — or whether observed cell-model effects have a different basis — is unresolved.
- Individual attribution in clinical data: All source-described observational clinical use involves Bronchogen co-administered with Chonluten. No clinical signal attributable to Bronchogen alone is present.
- Human translation: Whether the in vitro gene-regulation signal translates to any measurable change in airway mucosal function or clinical respiratory outcome in living subjects is not established. No in vivo or human biomarker data are present.
- Oral bioavailability: Whether orally dosed AEDL tetrapeptide survives gastrointestinal degradation and reaches the respiratory epithelium at concentrations relevant to reported in vitro effects has not been established.
- Long-term safety: No chronic toxicology, dose-escalation, or pharmacokinetic studies meeting Western regulatory standards have been published. Long-term effects of repeated transcription-level modulation in aging respiratory epithelium are unknown.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does GEDLE help only people whose airways are too dry or damaged, while potentially harming people whose airways already produce too much mucus?
If true, this finding would protect patients with asthma or COPD from a treatment that could worsen their mucus burden, while identifying a genuinely useful application for patients with mucosal atrophy after infection, chemotherapy, or rare ciliary disorders.
Does GEDLE only work in lung cells because those cells carry a special partner protein that other cell types lack?
Understanding why GEDLE targets the lung could explain the whole class of Russian bioregulator peptides and reveal whether any of them could be redirected to other tissues, which would be valuable for researchers developing organ-targeted therapies.
▸3-letter notation
▸citationbibtex
@peptide{pep10938,
sequence = {GEDLE},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}